Aim: The optimal maintenance therapy for active diffuse lupus nephritis remains to be established. In this study, we explored the efficacy and safety of tacrolimus for maintaining remission of active lupus nephritis compared to that of azathioprine. Methods: Seventy patients with biopsy-proven lupus nephritis who achieved remission were enrolled in nine nephrology centers in China from 2006 to 2008. Patients were randomized either to tacrolimus plus prednisone (n = 34) or azathioprine plus prednisone (n = 36) for six months. Tacrolimus was titrated to achieve a trough blood concentration of 4–6 ng/mL, and the dosage of azathioprine was 2 mg/kg/d. Prednisone was administered at a dose of 10 mg/d to both groups. The primary outcome was incidence of relapse. Response, clinical parameters and adverse effects were secondary endpoints. Results: After six months of therapy, two of the azathioprine-treated patients developed renal relapse compared to none of the tacrolimus-treated patients (p = 0.49; odds ratio, 1.06; 95% CI (0.98, 1.15)). Leucopenia (defined as < 2000 cells per cubic millimeter) was significantly more frequent in the azathioprine group than the tacrolimus group (47% vs. 9%, p < .001). Conclusion: In conjunction with prednisone, maintenance therapy with tacrolimus and azathioprine has a similar low rate of renal relapse, and the tacrolimus regimen has a more favorable safety profile, with less leucopenia. However, since our study lacked sufficient power, longer follow-up is needed to draw final conclusions.
ContrerasGPardoVLeclercqB. Sequential therapies for proliferative lupus nephritis. N Engl J Med2004; 350: 971–980.
2.
ChanTMTseKCTangCSLaiKNLiFK. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus2005; 14: 265–272.
3.
HoussiauFAVasconcelosCD'CruzD. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum2004; 50: 3934–3940.
4.
HoussiauFAD'CruzDSangleS. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis2010; 69: 2083–2089.
5.
Abstracts of the 9th International Congress on SLE. June 24-27 2010. Vancouver, Canada. Lupus 2010; 19 Suppl 1: 1–185.
6.
Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886–1895.
7.
MoroniGDoriaAMoscaM. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol2006; 1: 925–932.
8.
ChenWTangXLiuQ. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis2011; 57: 235–244.
9.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
10.
WeeningJJD'AgatiVDSchwartzMM. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol2004; 15: 241–250.
11.
SinclairAAppelGDooleyMA. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus2007; 16: 972–980.
GladmanDDGoldsmithCHUrowitzMB. Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol1994; 21: 1468–1471.
14.
VercauterenSBBosmansJLElseviersMMVerpootenGADe BroeME. A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int1998; 54: 536–545.
15.
TseKCLamMFTangSCTangCSChanTM. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus2007; 16: 46–51.
16.
SzetoCCKwanBCLaiFM. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford)2008; 47: 1678–1681.
17.
MyungSJYooBLeeKH. A case of systemic lupus erythematosus developing two years after remission of thrombotic thrombocytopenic purpura. Korean J Intern Med1996; 11: 178–182.
18.
KorbetSMLewisEJSchwartzMMReichlinMEvansJRohdeRD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis2000; 35: 904–914.
19.
TextorSCWiesnerRWilsonDJ. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation1993; 55: 1332–1339.
20.
TextorSCBurnettJCJr.RomeroJC. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int1995; 47: 1426–1433.
21.
FaulCDonnellyMMerscher-GomezS. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nature medicine2008; 14: 931–938.
22.
WangYJaradGTripathiP. Activation of NFAT signaling in podocytes causes glomerulosclerosis. J Am Soc Nephrol2010; 21: 1657–1666.
23.
CattranDCAlexopoulosEHeeringP. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations. Kidney Int2007; 72: 1429–1447.
